{
    "Rank": 1008,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00199797",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "LUD2003-005"
                },
                "Organization": {
                    "OrgFullName": "Ludwig Institute for Cancer Research",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer",
                "OfficialTitle": "Phase I Trial of huA33 Plus 5-fluorouracil (5-FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2022",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "April 18, 2005",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "November 8, 2006",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "April 1, 2016",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 12, 2005",
                "StudyFirstSubmitQCDate": "September 12, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 20, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "May 21, 2021",
                "ResultsFirstSubmitQCDate": "May 21, 2021",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "June 16, 2021",
                    "ResultsFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "October 3, 2022",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 10, 2022",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Ludwig Institute for Cancer Research",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America. In the search for new therapies, monoclonal antibodies have been developed to specifically target human colon cancer cells. huA33 is an antibody that reacts with the A33 antigen which is produced by colorectal cancers. Prior studies have shown that administration of the huA33 antibody may delay the growth of tumor cells producing the specific antigen. Oxaliplatin and 5-fluorouracil (5-FU) are cytotoxic agents which are considered as standard treatment in metastatic colorectal cancer. Leucovorin (folinic acid) is a vitamin which enhances the effect of 5-FU. Eligible patients with advanced colorectal cancer will receive huA33 10 mg/m2 by intravenous (IV) infusion weekly for twelve weeks. Starting on Study Day 15 (week 3), 5-FU, leucovorin, and oxaliplatin will be administered every 2 weeks for 10 weeks. Patients will be evaluated weekly for toxicity. Blood samples will be obtained every week for hematology and serum biochemistry analysis and for determination of human anti-human antibodies (HAHA). In patients with measurable disease, tumors will be assessed by the appropriate scan at baseline and at the end of the thirteen week cycle. The primary objective of this study is to assess the safety of huA33 + 5-FU + leucovorin + oxaliplatin. The secondary objective is to measure the immunogenicity of huA33 when given in combination with 5-FU plus leucovorin and oxaliplatin and to document tumor responses.",
                "DetailedDescription": "Purpose of the Research Study:\n\nhuA33 is an antibody that reacts with the A33 antigen which is produced by colorectal cancers. Prior studies have shown that application of the huA33 antibody may delay the growth of tumor cells producing the respective antigen.\n\nOxaliplatin and 5-FU are cytotoxic agents which are considered as standard treatment in metastatic colorectal cancer. Leucovorin is a vitamin which enhances the effect of 5-FU.\n\nThe primary purpose of this study is to determine whether the combination huA33 plus oxaliplatin, 5-FU and leucovorin is safe and what side effects occur.\n\nDescription of Research Procedures:\n\nThe first step is to determine whether or not patients are eligible for participation in the study. Apart from general blood tests and x-ray studies needed, this involves testing with regard to some special requirements:\n\nThree tests of stool to determine if it is positive for blood.\nWomen of childbearing age must have a negative pregnancy test.\nIf patients ever had a treatment with similar substances like huA33 before, a blood sample needs to be tested for antibodies that may have developed against huA33.\n\nAfter eligibility is established, huA33 will be administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2. Starting on day 15 and continuing every second week, oxaliplatin, 5-FU and leucovorin are administered. Oxaliplatin and leucovorin will be given as infusions over 2 hours. Afterwards patients will receive a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin will be 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion. A complete treatment cycle consists of 12 weekly treatment days.\n\nPatients will have an interview with their doctor and a physical examination before the first day of treatment and before each therapy. Standard blood tests as well as special blood tests to measure a possible reaction of the immune system to the huA33 antibody will be done weekly and before the treatment is started. The amount of blood to be drawn will be 20-30 ml during one cycle of the study.\n\nX-rays and/or CT scans to measure the extent of the disease will be done at the start and at week 13, which is considered to be the first day of the next cycle. Patients may continue with this treatment for up to 2 cycles."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Colorectal Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Colorectal Cancer",
                        "huA33",
                        "antibody",
                        "chemotherapy"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "20",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "huA33 antibody plus chemotherapy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Oxaliplatin",
                                    "Drug: 5-Fluorouracil",
                                    "Drug: Leucovorin",
                                    "Drug: huA33"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Oxaliplatin",
                            "InterventionDescription": "Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "huA33 antibody plus chemotherapy"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Eloxatin"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "5-Fluorouracil",
                            "InterventionDescription": "The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "huA33 antibody plus chemotherapy"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "5-FU"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Leucovorin",
                            "InterventionDescription": "Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "huA33 antibody plus chemotherapy"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "folinic acid"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "huA33",
                            "InterventionDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "huA33 antibody plus chemotherapy"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.",
                            "PrimaryOutcomeDescription": "Patients were evaluated weekly for toxicity. Blood samples were obtained every week for hematology and serum biochemistry analysis. All adverse events, which occurred after the signing of informed consent were documented in the case report form. Toxicity was evaluated according to the National Cancer Institute CTCAE Scale (Version 3.0). All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 13.1 and classified by MedDRA system organ class (SOC) and preferred term. Treatment emergent adverse events (TEAEs) are any adverse events occurring or worsening after the first administration of study drug.",
                            "PrimaryOutcomeTimeFrame": "up to 26 weeks"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Immunogenicity of huA33 as Measured by the Number of Patients With Human Anti-human Antibodies (HAHA) When Given huA33 Together With Oxaliplatin and 5-FU Plus Leucovorin in Patients With Metastatic Colorectal Cancer.",
                            "SecondaryOutcomeDescription": "Serum samples were taken at baseline and prior to each administration of huA33.The samples were analyzed by surface plasmon resonance technology using a BIACORE 2000 instrument. All sera were analyzed at the end of the study. Patient serum was considered HAHA positive if the response unit (RU) value at a serum dilution of 1:100 exceeded a cutoff value, defined as the mean inter-patient baseline RU value + 3x the standard deviation (SD) of negative control sera at a serum dilution of 1:100. Results were reported as either positive or negative.",
                            "SecondaryOutcomeTimeFrame": "up to 26 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin.",
                            "SecondaryOutcomeDescription": "Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al. J Natl Cancer Inst 92: 205-216 2000) at baseline and at the end of each cycle.\n\nPer RECIST, target lesions were categorized as follows: complete response (CR): disappearance of all target lesions; partial response (PR): \u2265 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): \u2265 20% increase in the sum of the longest diameter of target lesions; stable disease (SD): small changes that do not meet above criteria.",
                            "SecondaryOutcomeTimeFrame": "up to 26 weeks"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nPatients will be eligible for enrollment if they fulfill all of the following criteria:\n\nMetastatic colorectal cancer.\nHistologically or cytologically proven colorectal cancer.\nExpected survival of at least 4 months.\nNot more than 2 different pretreatment regimens.\nEastern Cooperative Oncology Group (ECOG) performance status 0-2.\n\nWithin the 2 weeks prior to the first dose of huA33, the following vital laboratory parameters:\n\nLab Parameter Range\n\nNeutrophil count \u2265 1.5 x 10E9/L\nPlatelet count \u2265 150 x 10E9/L\nSerum bilirubin \u2264 2 mg/dL\nCreatinine clearance >50 ml/ min\nAge \u2265 18 years.\nAble and willing to give valid written informed consent.\n\nExclusion Criteria:\n\nPatients will be excluded from the study for any of the following reasons:\n\nUntreated active metastatic disease to the central nervous system defined as new or enlarging lesions on CT or MRI.\nSurgery or radiotherapy of brain metastases within 3 months prior to the first dose of huA33.\nMetastatic disease involving > 50% of liver volume.\nOther serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.\nChemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing (6 weeks for nitrosoureas).\nPrevious treatment with oxaliplatin.\n\nPrevious treatment with huA33 monoclonal antibody or antibody fragment.\n\na. Positive huA33 HAHA titer - defined as greater than 3 standard deviations above the mean patient normal range by Biacore analysis.\n\nConcomitant treatment with systemic corticosteroids. Topical or inhalational corticosteroids are permitted.\nKnown HIV, Hepatitis B or C positivity.\nMental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.\nLack of availability of the patient for clinical and laboratory follow-up assessment.\nParticipation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.\nPregnancy or breastfeeding.\nWomen of childbearing potential: Refusal or inability to use effective means of contraception.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Christoph Renner, MD",
                            "OverallOfficialAffiliation": "Universit\u00e4tsspital Z\u00fcrich, Switzerland",
                            "OverallOfficialRole": "Principal Investigator"
                        },
                        {
                            "OverallOfficialName": "Alexander Knuth, MD",
                            "OverallOfficialAffiliation": "Universit\u00e4tsspital Z\u00fcrich, Switzerland",
                            "OverallOfficialRole": "Principal Investigator"
                        },
                        {
                            "OverallOfficialName": "Elke J\u00e4ger, MD",
                            "OverallOfficialAffiliation": "Krankenhaus Nordwest, Germany",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Krankenhaus Nordwest",
                            "LocationCity": "Frankfurt",
                            "LocationZip": "60488",
                            "LocationCountry": "Germany"
                        },
                        {
                            "LocationFacility": "UniversitaetsSpital Zuerich",
                            "LocationCity": "Zurich",
                            "LocationZip": "CH-8091",
                            "LocationCountry": "Switzerland"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "10655437",
                            "ReferenceType": "background",
                            "ReferenceCitation": "Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205."
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "huA33 Antibody Plus Chemotherapy",
                            "FlowGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "20"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "17"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Progressive Disease",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Adverse Event",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Physician Decision",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselinePopulationDescription": "All patients who received at least one dose of huA33.",
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "huA33 Antibody Plus Chemotherapy",
                            "BaselineGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "20"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Full Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "66",
                                                                "BaselineMeasurementLowerLimit": "37",
                                                                "BaselineMeasurementUpperLimit": "74"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "9"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "19"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "20"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "Switzerland",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineClassTitle": "Germany",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and Serious TEAEs in Patients With Metastatic Colorectal Cancer.",
                            "OutcomeMeasureDescription": "Patients were evaluated weekly for toxicity. Blood samples were obtained every week for hematology and serum biochemistry analysis. All adverse events, which occurred after the signing of informed consent were documented in the case report form. Toxicity was evaluated according to the National Cancer Institute CTCAE Scale (Version 3.0). All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) Version 13.1 and classified by MedDRA system organ class (SOC) and preferred term. Treatment emergent adverse events (TEAEs) are any adverse events occurring or worsening after the first administration of study drug.",
                            "OutcomeMeasurePopulationDescription": "All patients who received at least one dose of huA33.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "up to 26 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "huA33 Antibody Plus Chemotherapy",
                                        "OutcomeGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Number of patients with treatment emergent adverse events",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of patients with treatment emergent adverse events Grade 3 or above",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "17"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of patients with treatment emergent adverse events which resulted in death",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of patients with treatment emergent adverse events related to treatment",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "18"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Number of patients with serious adverse events",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Immunogenicity of huA33 as Measured by the Number of Patients With Human Anti-human Antibodies (HAHA) When Given huA33 Together With Oxaliplatin and 5-FU Plus Leucovorin in Patients With Metastatic Colorectal Cancer.",
                            "OutcomeMeasureDescription": "Serum samples were taken at baseline and prior to each administration of huA33.The samples were analyzed by surface plasmon resonance technology using a BIACORE 2000 instrument. All sera were analyzed at the end of the study. Patient serum was considered HAHA positive if the response unit (RU) value at a serum dilution of 1:100 exceeded a cutoff value, defined as the mean inter-patient baseline RU value + 3x the standard deviation (SD) of negative control sera at a serum dilution of 1:100. Results were reported as either positive or negative.",
                            "OutcomeMeasurePopulationDescription": "All patients who received at least one dose of huA33.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "up to 26 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "huA33 Antibody Plus Chemotherapy",
                                        "OutcomeGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin,5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "Patients with positive HAHA response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "6"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Patients with negative HAHA response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "14"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Tumor Response in Patients With Metastatic Colorectal Cancer Receiving huA33, Oxaliplatin and 5-FU Plus Leucovorin.",
                            "OutcomeMeasureDescription": "Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al. J Natl Cancer Inst 92: 205-216 2000) at baseline and at the end of each cycle.\n\nPer RECIST, target lesions were categorized as follows: complete response (CR): disappearance of all target lesions; partial response (PR): \u2265 30% decrease in the sum of the longest diameter of target lesions; progressive disease (PD): \u2265 20% increase in the sum of the longest diameter of target lesions; stable disease (SD): small changes that do not meet above criteria.",
                            "OutcomeMeasurePopulationDescription": "Patients who received huA33 and were evaluable for response. One patient was not evaluable.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Count of Participants",
                            "OutcomeMeasureUnitOfMeasure": "Participants",
                            "OutcomeMeasureTimeFrame": "up to 26 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "huA33 Antibody Plus Chemotherapy",
                                        "OutcomeGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin, 5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards, patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "19"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeCategoryTitle": "Complete Response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Partial Response",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Stable Disease",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeCategoryTitle": "Progressive Disease",
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventsTimeFrame": "up to 26 weeks",
                "EventsDescription": "All adverse events which occurred after signing informed consent were documented in the source records and on the respective case report form, regardless of the assumption of a causal relationship. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Scale (Version 3.0).Treatment emergent adverse events (TEAEs) are any adverse events occurring or worsening after the first administration of study drug.",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "huA33 Antibody Plus Chemotherapy",
                            "EventGroupDescription": "huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2 for 12 weeks.\n\nStarting on day 15 and continuing every second week, oxaliplatin,5-fluorouracil (5-FU) and leucovorin were also administered.\n\nOxaliplatin and leucovorin were given as infusions over 2 hours. Afterwards patients received a bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.\n\nThe doses of oxaliplatin were 85mg/m2, leucovorin 200mg/m2, 400mg/m2 of 5-FU as a bolus infusion and 600mg/m2 as a continuous infusion.\n\nA complete treatment cycle consisted of 12 weeks. Patients were eligible to receive an additional cycle in the absence of dose-limiting toxicity (DLT), immunogenicity (huA33 human anti-human antibodies {HAHA}) and disease progression.",
                            "EventGroupDeathsNumAffected": "1",
                            "EventGroupDeathsNumAtRisk": "20",
                            "EventGroupSeriousNumAffected": "11",
                            "EventGroupSeriousNumAtRisk": "20",
                            "EventGroupOtherNumAffected": "20",
                            "EventGroupOtherNumAtRisk": "20"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "Sudden death",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Chills",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Cholecystitis",
                            "SeriousEventOrganSystem": "Hepatobiliary disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Pyrexia",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hypersensitivity",
                            "SeriousEventOrganSystem": "Immune system disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Rash pruritic",
                            "SeriousEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Blood bilirubin increased",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Abdominal pain",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Performance status decreased",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Gastritis",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Arterial thrombosis limb",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Catheter placement",
                            "SeriousEventOrganSystem": "Surgical and medical procedures",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Chemotherapy",
                            "SeriousEventOrganSystem": "Surgical and medical procedures",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Device related infection",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Deep vein thrombosis",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventSourceVocabulary": "MedDRA (13.1)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Neutropenia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "13",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Anaemia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Leukopenia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Thrombocytopenia",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Bradycardia",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspnoea exertional",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Tachycardia",
                            "OtherEventOrganSystem": "Cardiac disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vertigo",
                            "OtherEventOrganSystem": "Ear and labyrinth disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "14",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Diarrhoea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Abdominal pain",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Abdominal pain upper",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dysgeusia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dyspepsia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Haemorrhoids",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Mucosal inflammation",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pyrexia",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Chills",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Asthenia",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Oedema peripheral",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Drug hypersensitivity",
                            "OtherEventOrganSystem": "Immune system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Nasopharyngitis",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sinusitis",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Weight decreased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Blood creatinine increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "C-reactive protein increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Respiratory rate increased",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Decreased appetite",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypokalaemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypomagnesaemia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Back pain",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain in extremity",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Polyneuropathy",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Sleep disorder",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Cough",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Epistaxis",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pruritis",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dermatitis allergic",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Dry skin",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Erythema",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Urticaria",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypotension",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hypertension",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "MedDRA (13.1)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "20"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "No",
                    "AgreementRestrictiveAgreement": "No"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Jonathan Skipper PhD",
                    "PointOfContactOrganization": "Ludwig Institute for Cancer Research",
                    "PointOfContactEMail": "jskipper@lcr.org",
                    "PointOfContactPhone": "12124501539"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000015179",
                            "ConditionMeshTerm": "Colorectal Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000007414",
                            "ConditionAncestorTerm": "Intestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000005770",
                            "ConditionAncestorTerm": "Gastrointestinal Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000005767",
                            "ConditionAncestorTerm": "Gastrointestinal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000003108",
                            "ConditionAncestorTerm": "Colonic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000007410",
                            "ConditionAncestorTerm": "Intestinal Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012002",
                            "ConditionAncestorTerm": "Rectal Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M17580",
                            "ConditionBrowseLeafName": "Colorectal Neoplasms",
                            "ConditionBrowseLeafAsFound": "Colorectal Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M10138",
                            "ConditionBrowseLeafName": "Intestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6026",
                            "ConditionBrowseLeafName": "Colonic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10134",
                            "ConditionBrowseLeafName": "Intestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14534",
                            "ConditionBrowseLeafName": "Rectal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000002955",
                            "InterventionMeshTerm": "Leucovorin"
                        },
                        {
                            "InterventionMeshId": "D000005472",
                            "InterventionMeshTerm": "Fluorouracil"
                        },
                        {
                            "InterventionMeshId": "D000077150",
                            "InterventionMeshTerm": "Oxaliplatin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007166",
                            "InterventionAncestorTerm": "Immunosuppressive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000000931",
                            "InterventionAncestorTerm": "Antidotes"
                        },
                        {
                            "InterventionAncestorId": "D000020011",
                            "InterventionAncestorTerm": "Protective Agents"
                        },
                        {
                            "InterventionAncestorId": "D000014803",
                            "InterventionAncestorTerm": "Vitamin B Complex"
                        },
                        {
                            "InterventionAncestorId": "D000014815",
                            "InterventionAncestorTerm": "Vitamins"
                        },
                        {
                            "InterventionAncestorId": "D000018977",
                            "InterventionAncestorTerm": "Micronutrients"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M9874",
                            "InterventionBrowseLeafName": "Immunoglobulins",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M5881",
                            "InterventionBrowseLeafName": "Leucovorin",
                            "InterventionBrowseLeafAsFound": "Catheter",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M8290",
                            "InterventionBrowseLeafName": "Fluorouracil",
                            "InterventionBrowseLeafAsFound": "Visit",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M1674",
                            "InterventionBrowseLeafName": "Oxaliplatin",
                            "InterventionBrowseLeafAsFound": "Function",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3915",
                            "InterventionBrowseLeafName": "Antibodies",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M8308",
                            "InterventionBrowseLeafName": "Folic Acid",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M28923",
                            "InterventionBrowseLeafName": "Levoleucovorin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9902",
                            "InterventionBrowseLeafName": "Immunosuppressive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3940",
                            "InterventionBrowseLeafName": "Antidotes",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M21559",
                            "InterventionBrowseLeafName": "Protective Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M17248",
                            "InterventionBrowseLeafName": "Vitamins",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M17236",
                            "InterventionBrowseLeafName": "Vitamin B Complex",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20699",
                            "InterventionBrowseLeafName": "Micronutrients",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M16575",
                            "InterventionBrowseLeafName": "Trace Elements",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "T446",
                            "InterventionBrowseLeafName": "Folic Acid",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "T447",
                            "InterventionBrowseLeafName": "Folinic Acid",
                            "InterventionBrowseLeafAsFound": "Users",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "T448",
                            "InterventionBrowseLeafName": "Folate",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "T475",
                            "InterventionBrowseLeafName": "Vitamin B9",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Micro",
                            "InterventionBrowseBranchName": "Micronutrients"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Hemat",
                            "InterventionBrowseBranchName": "Hematinics"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Vi",
                            "InterventionBrowseBranchName": "Vitamins"
                        }
                    ]
                }
            }
        }
    }
}